Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Oxford BioDynamics ( (GB:OBD) ) has issued an announcement.
Oxford BioDynamics has announced that long-serving non-executive director Stephen Diggle has stepped down from the board with immediate effect, in line with previously signalled plans and corporate governance practice after nine years in the role. While Diggle departs the board, his firm Vulpes Investment Management remains the company’s largest shareholder and will nominate a new non-executive director in due course, ensuring continued influence over governance and strategic direction at a time when the diagnostics specialist is commercialising its EpiSwitch-based tests and seeking to strengthen its market position.
The most recent analyst rating on (GB:OBD) stock is a Hold with a £0.26 price target. To see the full list of analyst forecasts on Oxford BioDynamics stock, see the GB:OBD Stock Forecast page.
Spark’s Take on GB:OBD Stock
According to Spark, TipRanks’ AI Analyst, GB:OBD is a Underperform.
Oxford BioDynamics faces significant financial and technical challenges, with persistent losses, high leverage, and bearish market momentum. The negative P/E ratio and lack of dividend yield further impact the stock’s valuation. The overall score reflects these substantial risks, with financial performance being the most critical factor.
To see Spark’s full report on GB:OBD stock, click here.
More about Oxford BioDynamics
Oxford BioDynamics Plc is an international biotechnology company focused on precision clinical diagnostics, developing and commercializing blood-based tests that use its proprietary EpiSwitch 3D genomics platform to predict disease presence and treatment response. Its main products include the EpiSwitch PSE prostate cancer screening test, which significantly improves the predictive accuracy of standard PSA testing, and the EpiSwitch CiRT test, which predicts patient response to immuno-oncology checkpoint inhibitor therapies. The company is expanding its test pipeline into oncology, neurology, inflammation, hepatology and animal health, and operates laboratories in Oxford, UK, Maryland, USA, and Penang, Malaysia, with its shares traded on AIM in London.
Average Trading Volume: 26,744,593
Technical Sentiment Signal: Strong Sell
Current Market Cap: £11.59M
See more insights into OBD stock on TipRanks’ Stock Analysis page.